A5401 COVID Supplement

$3,770,048UM1FY2020AINIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Paper 39723835 Paper 39704169 Paper 39630590 Paper 39605411 Paper 39484497 Paper 39477924 Paper 39435321 Paper 39431505 Paper 39374532 Paper 39356094 Paper 39302766 Paper 39287554 Paper 39135958 Paper 39101720 Paper 39074163 Paper 39066509 Paper 39028902 Paper 39012226 Paper 38985541 Paper 38961547 Paper 38923420 Paper 38833307 Paper 38746756 Paper 38746144 Paper 38716969 Paper 38699319 Paper 38692296 Paper 38684100 Paper 38659142 Paper 38635853 Paper 38597667 Paper 38564365 Paper 38551350 Paper 38489580 Paper 38462673 Paper 38408216 Paper 38372621 Paper 38370806 Paper 38340419 Paper 38332460 Paper 38329130 Paper 38253253 Paper 38236978 Paper 38180893 Paper 38175824 Paper 38160309 Paper 38113685 Paper 38112526 Paper 38051788 Paper 38034739 Paper 37971239 Paper 37957382 Paper 37949070 Paper 37910437 Paper 37855026 Paper 37820116 Paper 37768207 Paper 37745410 Paper 37744732 Paper 37744358 Paper 37740554 Paper 37696248 Paper 37650237 Paper 37650236 Paper 37650235 Paper 37650234 Paper 37650233 Paper 37650232 Paper 37650231 Paper 37650230 Paper 37632053 Paper 37601728 Paper 37581929 Paper 37530525 Paper 37506723 Paper 37503623 Paper 37486775 Paper 37429153 Paper 37368929 Paper 37315296 Paper 37306344 Paper 37279602 Paper 37227925 Paper 37183889 Paper 37163616 Paper 37162333 Paper 37099295 Paper 37098852 Paper 37068272 Paper 37062293 Paper 37034605 Paper 37017075 Paper 36993692 Paper 36993419 Paper 36931242 Paper 36881933 Paper 36877848 Paper 36853100 Paper 36851191 Paper 36825498

Abstract

ABSTRACT The AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.

View original record on NIH RePORTER →